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Introduction
We present the case of a female infant presenting after a
ventricular ﬁbrillation arrest found to have ectopic atrial
tachycardia (EAT). Evaluation revealed a likely pathogenic
variant in SOS1 not previously reported in affected individuals. SOS1 variants are associated with Noonan syndrome,
which belongs to a family of related genetic syndromes
affecting the RAS/MAPK signaling pathway. To date, this
is the ﬁrst case reported of a ventricular ﬁbrillation arrest in
a patient with a RASopathy-related variant prior to development of the typically associated structural cardiac phenotype
and may represent a previously unrecognized etiology of
sudden death during infancy.

KEY TEACHING POINTS
 RASopathies can present with an arrhythmia
phenotype that precedes other typical structural
cardiac ﬁndings of valvular disease or hypertrophic
cardiomyopathy.
 Complex ventricular ectopy is a rare ﬁnding in
RASopathies; however, it may result in unexpected
sudden cardiac death.
 Genetic testing in infantile aborted sudden cardiac
death is important, as arrhythmia phenotypes can
present prior to typical syndrome ﬁndings.

Case report
An 8-week-old former 36-week female infant presented
following a documented ventricular ﬁbrillation arrest at
home. The patient was at her baseline health the previous
day; however, she did not rouse for her usual morning feed.
She was found limp and pale with agonal breathing in her
bassinet. Rescue breaths were initiated and on arrival Emergency Medical Services noted the patient to be pulseless.
Cardiopulmonary resuscitation was initiated and an external
deﬁbrillator revealed coarse ventricular ﬁbrillation
(Figure 1a). Initial shock of 10 J was given with conversion
to an atrial rhythm with aberrant ventricular conduction. The
patient developed increasing frequency of ectopy (Figure 1b)
before degenerating to ventricular ﬁbrillation. A second shock
with 20 J was unsuccessful. A third shock of 20 J successfully
converted the rhythm to sinus with aberrant ventricular
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conduction and atrial ectopy (Figure 1c) with return of spontaneous circulation. No epinephrine or amiodarone was given
during the resuscitation. Review of the deﬁbrillator tracings
show 14 minutes from pad placement to ROSC and total arrest
time was estimated at 20 minutes.
On arrival in the ICU the patient was found to have incessant, nonsustained EAT (Figure 2a) with ventricular rates up
to 300 beats per minute in the setting of seizure activity. Intravenous lorazepam was given with cessation of seizure activity and amiodarone boluses were given (total 5 mg/kg), with
transient establishment of sinus rhythm. The QTc was noted
to be .500 ms (Figure 2b) and Brugada positioning of leads
was unrevealing. Transthoracic echocardiogram demonstrated a structurally normal heart with normal valve
morphology and a patent foramen ovale with left-to-right
ﬂow. The initial ejection fraction was 49% and there was
no ventricular hypertrophy, dilation, or noncompaction noted
(Figure 3). The patient was started on an esmolol infusion
titrated to 225 mcg/kg/min with frequent, nonsustained
breakthrough of EAT. Over the next 24 hours there was
normalization of the QTc interval with normal T-wave
morphology (Figure 2c). A procainamide challenge was
performed and was negative. Cardiac magnetic resonance
imaging showed normalization of ventricular function
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Figure 1 A: The initial rhythm recorded on external deﬁbrillator demonstrating coarse ventricular ﬁbrillation. B: After initial deﬁbrillation, rhythm strip
demonstrating increasing burden of ectopy preceding degeneration to ventricular ﬁbrillation. C: Rhythm following third deﬁbrillation demonstrating probable
sinus rhythm with atrial ectopy and aberrant ventricular conduction.

without late gadolinium enhancement. Esmolol was titrated
to 400 mcg/kg/min with continued occasional nonsustained
breakthrough. The patient was transitioned to sotalol that
was titrated to 6.8 mg/kg/day (132 mg/m2/day), with only
rare nonsustained breakthrough achieved by day 5.
Laboratory evaluation included an initial capillary blood gas
remarkable for acidosis with pH 7.21, pCO2 25 mm Hg, HCO3
22 mmol/L, and base excess -14 mmol/L. Lactate was 0.9
mmol/L with glucose 86 mg/dL. Normal results were found
for complete blood count with differentiation, basic metabolic
panel, liver function panel, thyroid function panel, cortisol
level, erythrocyte sedimentation rate, and C-reactive protein.
Severe acute respiratory syndrome coronavirus 2 screen was
negative. Metabolic evaluation included an unremarkable urine
organic acids and acylcarnitine proﬁle.
The genetics team was consulted and a standard 3generation family history was obtained with the proband
the second biological child of the parents. The older sibling
was 2 years old and without known medical conditions. The
mother had history of pancreatic cancer status post resection

and chemotherapy. The paternal grandfather died of a
presumed myocardial infarction in the ﬁfth decade of life;
however, no autopsy was performed. There was no family
history of congenital heart disease, arrhythmia, sudden
death, cardiomyopathy, recurrent syncope, congenital deafness, seizure, miscarriage, or developmental delay. Electrocardiograms were obtained on the parents and were
normal. Genetic testing was performed using a comprehensive arrhythmia and cardiomyopathy NGS panel with
maternal and paternal segregation studies. This revealed a
de novo likely pathogenic (PS2, PM2, PM5, PP3) variant
c.1649T.G (p.Leu550Arg) in SOS1 (GRCh37/UCSC
hg13: 2-39249920-A-C). Owing to the presentation of
aborted sudden cardiac death, the patient underwent dualchamber epicardial implantable cardioverter-deﬁbrillator
implantation prior to discharge.

Discussion
We present a case of aborted sudden cardiac death in a previously healthy infant found to have a likely pathogenic SOS1
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Figure 2 A: Initial 12-lead electrocardiogram (ECG) on arrival in the
intensive care unit, demonstrating frequent nonsustained episodes of ectopic
atrial tachycardia. B: A 12-lead ECG obtained following conversion to sinus
rhythm with a 5 mg/kg amiodarone bolus showing a prolonged QTc. C: A
12-lead ECG obtained 24 hours after presentation showing normalization
of the QTc and T-wave morphology.

variant, incessant EAT, without typical phenotypic ﬁndings of
Noonan syndrome. This case reports novel ﬁndings of disease
associated with this SOS1 variant as well as a documented ventricular ﬁbrillation arrest in a RASopathy prior to development
of typical structural cardiac phenotypic ﬁndings.
The RASopathies are a family of related genetic syndromes
resulting from gain-of-function mutations in genes involving
the RAS/MAPK signaling pathway and include Noonan syndrome (OMIM #163950), Costello syndrome (OMIM
#218040), Noonan syndrome with multiple lentigines
(OMIM #151100), and cardiofaciocutaneous syndrome
(OMIM #115050).1 These syndromes have overlapping
phenotypic features including skeletal, dermatologic, and neurocognitive ﬁndings. Cardiac phenotypes are also common,
including valve stenosis or dysplasia, atrial and ventricular
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septal defects, and hypertrophic cardiomyopathy (HCM).2
More recently, the electrophysiologic phenotype has been
described, with increased incidence of multifocal atrial tachycardia and EAT that occurred independent of HCM or valvular
stenosis in 36% of patients and can be clinically challenging to
control.3 It is theorized that calcium dysregulation results in
triggered activity giving rise to the atrial tachycardia, as well
as contributing to the cardiomyopathy phenotype.3,4
The SOS1 gene is located on chromosome 2p22 and
encodes a guanine nucleotide exchange factor for RAS proteins. Gain-of-function mutations have been associated
with Noonan syndrome, potentially accounting for up to
28% of cases.1,5,6 SOS1-mediated Noonan syndrome can
have a mild phenotype, which may not be apparent until
older ages when neurocognitive ﬁndings become more
apparent, consistent with our presentation.6,7 Our patient
was found to have a de novo missense mutation in a highly
conserved amino acid residue of the pleckstrin homology
domain–RAS exchanger motif domain linker that has not
previously been reported. There was a single ﬁnding of
this variant in the gnomAD dataset with the highest frequency 0.0024% (northwestern European). A similar
missense variant affecting this residue (p.Leu550Pro, ClinVar VCV000040680) was shown to increase RAS
exchange rates in vitro. Additionally, it has been reported
in multiple individuals with Noonan syndrome and has
been shown to cosegregate with disease within families.6,8,9
Out-of-hospital cardiac arrest remains a rare entity in the
pediatric population, though arrhythmias are common in
the postarrest phase, likely owing to reperfusion, cytokine
release, myocardial dysfunction, and associated catecholamine administration.10,11 While a variety of ectopy can
be observed during this phase in pediatrics, incessant atrial
tachycardia is atypical and is potentially more consistent
with the arrhythmia phenotype seen in Noonan syndrome.10
Unexpected sudden death has also been reported in Noonan
syndrome and is presumed to be due to ventricular arrhythmias in the setting of HCM and pulmonary stenosis.12 To
the extent of our knowledge, our case is the ﬁrst reported
ventricular ﬁbrillation arrest associated with a RASopathy
in the absence of the typical structural cardiac phenotypes
of HCM or pulmonary stenosis. In fact, complex ventricular
arrhythmias were previously rarely reported in these syndromes and not with documented cardiac arrest. Recently,
Aly et al reported a case of neonatal Noonan syndrome
with pulmonary valve stenosis, monocytosis, myeloproliferative disorder, and accelerated idioventricular rhythm
resulting in severe hemodynamic compromise and ultimately contributing to patient demise.13 The accelerated
idioventricular rhythm occurred following intervention to
attempt right ventricular decompression and required extracorporeal membrane oxygenation support. Ultimately the
rhythm was unable to be controlled and contributed to
patient demise. This was the ﬁrst reported complex
ventricular arrhythmia affecting patient survival in RIT1
variant–mediated Noonan syndrome. Our patient, however,
did not have the cardiac manifestations of pulmonary valve
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Figure 3 Apical 4-chamber view at (A) end diastole and (B) end systole at initial presentation. M-mode from (C) parasternal short axis view at presentation.
Ejection fraction was 48.7% and shortening fraction 24.8%, which improved to 63.3% and 38.5%, respectively, at 1 month. There was normal valve morphology
and function without evidence of ventricular hypertrophy, dilation, or noncompaction.

stenosis or history of intervention associated with her
arrhythmia.
The limitation to this case report is the lack of deﬁnitive
association of the SOS1 variant with the presentation.
In vitro studies have not been performed to conﬁrm gainof-function effects for this variant; however, comparison
to similar variants is supportive. As this is a de novo variant
in the family that has not previously been described, we are
also unable to demonstrate cosegregation with disease. Our
patient does not have typical features of Noonan syndrome
at this time; however, the milder phenotype of SOS1-associated disease may become apparent over time and conﬁrm
this variant is putative for Noonan syndrome. She does
demonstrate the arrhythmia phenotype of nonreentrant
atrial tachycardia associated with RASopathies, which has
been shown to manifest independently of other characteristic ﬁndings.3 Potentially this variant will be further
clariﬁed over time as additional carriers are reported.

Conclusion

We report the ﬁrst case of a ventricular ﬁbrillation arrest in a
female infant with an SOS1 variant in the absence of structural cardiac manifestations. This may represent a previously
unrecognized etiology of unexpected sudden cardiac death in
infants presumed healthy. Additionally, it supports the theory
of ventricular arrhythmias as likely etiology of unexpected
sudden death in patients with RASopathies.
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